These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 2215973)

  • 1. Levodopa therapy in Parkinson's disease.
    Koller WC; Hubble JP
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 40-7; discussion 47-9. PubMed ID: 2215973
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors that influence the occurrence of response variations in Parkinson's disease.
    de Jong GJ; Meerwaldt JD; Schmitz PI
    Ann Neurol; 1987 Jul; 22(1):4-7. PubMed ID: 3631919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current approaches in the treatment of Parkinson disease].
    Caraceni T; Geminiani G; Tamma F
    Recenti Prog Med; 1989 Dec; 80(12):686-91. PubMed ID: 2576471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
    Indo T
    Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
    [No Abstract]   [Full Text] [Related]  

  • 6. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
    Narabayashi H
    No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological approaches to Parkinson's disease in the different phases of evolution.
    Giovannini P; Piccolo I; Scigliano G; Caraceni T
    J Neural Transm Suppl; 1986; 22():173-87. PubMed ID: 3097255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 12. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluctuations in response to L-dopa in Parkinson's disease may be explained by changes in striatal dopamine turnover.
    Rose S; Thomas K; Jenner P; Marsden CD
    Br J Pharmacol; 1989 Dec; 98 Suppl():816P. PubMed ID: 2611523
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 16. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN; Meerwaldtt JD
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 18. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.